Adequate Platelet Function Inhibition Confirmed By Two Inductive Agents Predict Lower Recurrence Of Ischemic Stroke/TIA

Objective:This study was aimed to investigate a new type platelet function analyzer with two different inductive agents to detect platelet functions and access its association with recurrent ischemic stroke/TIA.Methods:The study included 738 ischemic stroke/TIA patients.On Day 0,3,and 9after antiplatelet therapy,platelet function tests were determined by Maximum aggregation rate（MAR）using a new type of PL-11 platelet function analyzer and phase matching reagents.Two induction agents were applied,including arachidonicacid（AA）and adenosine diphosphate（ADP）.At 3-month follow-up,recurrence of stroke/TIA were recorded.Results:In our study,cut-off values of adequate platelet function inhibition were MAR_ADP<35%,MAR_AA<35%.The data showed that antiplatelet therapy could reduce the Maximum aggregation rate.More important,at 3-month follow-up,adequate platelet function inhibition of either MAR_ADP or MAR_AA wasn’t associated with the recurrence of stroke/TIA,but adequate platelet function inhibition of not only MAR_ADP but also MAR_AA predict lower recurrence of stroke/TIA.(0/121（0.00%）vs.18/459（3.92%,P=0.0188）.Conclusion:The platelet function tested by PL-11 with inductive agents of ADP and AA demonstrated that adequate inhibition of both MAR_ADP and MAR_AA could predict lower risk of ischemic stroke/TIA recurrence.